Stockscreener 앱 받기
7.36
18.52%
1.15
Gt Biopharma Inc 주식(GTBP)의 최신 뉴스
Form S-1 GT Biopharma Inc For: 9 October By Investing.com - Investing.com Canada
Gt Biopharma Selling Stockholders To Offer Up To 13,502,835 Shares Of Common Stock - TradingView
TRex Bio Files for Nasdaq IPO - Yahoo! Finance Canada
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
GT Biopharma regains Nasdaq compliance: what it means for GT Biopharma stock - AD HOC NEWS
GT Biopharma sells USD 7.75 million: what it means for GT Biopharma stock - AD HOC NEWS
With $31.2M left to sell, GT Biopharma (GTBP) has made its first equity sale. - stocktitan.net
BioHarvest Sciences launches buyback of up to 5% of shares - Yahoo! Finance Canada
GT Biopharma Regains Nasdaq Minimum Bid Compliance - The Globe and Mail
GT Biopharma Regains Nasdaq Minimum Bid Compliance - The Globe and Mail
GT Biopharma regains Nasdaq $1.00 minimum bid compliance after 10-day stretch - TradingView
GT Biopharma Expands Series M Preferred Financing Agreement - The Globe and Mail
GT Biopharma Upsizes Preferred Stock Offering to US$7.75 Million With New Investor - minichart.com.sg
GT Biopharma Increases Series M Preferred Stock Private Placement with New Investor - Kalkine Media
GT Biopharma Expands Private Placement to $8.61M Stated Value, Adds Greenshoe Up to $34.7M - TradingView
GT Biopharma (Nasdaq:GTBP)Stock Analysis - Simply Wall Street
New investor hits 9.99% ceiling in GT Biopharma (GTBP) - Stock Titan
GT Biopharma announces $7.45 million private placement of preferred stock and warrants - Investing.com Nigeria
Form 8K GT Biopharma Inc For: 15 September By Investing.com - Investing.com Nigeria
Form 8K GT Biopharma Inc For: 15 September By Investing.com - Investing.com UK
GT Biopharma announces $7.45 million private placement of preferred stock and warrants - Investing.com UK
Form 8K GT Biopharma Inc For: 15 September By Investing.com - Investing.com South Africa
Why Has GT Biopharma (GTBP) Become a Talking Point? - Kalkine Media
GT Biopharma, Inc. announced that it expects to receive $30 million in funding - marketscreener.com
Why Has GT Biopharma (GTBP) Become a Talking Point? - kalkinemedia.com
GTBP: Phase I TriKE trials show early promise, with key data expected soon and broad expansion potential - TradingView
Price to sales ratio of GT Biopharma Inc – MUN:OXI - tradingview.com
EBITDA per share of GT Biopharma Inc – MUN:OXI - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
GTBP Price Today: GT Biopharma Inc. Stock Price, Quote & Chart | MEXC - MEXC
GT Biopharma Pops Ahead of Presentation - Baystreet.ca
GT Biopharma Pops Ahead of Presentation - Baystreet.ca
GT Biopharma Pops Ahead of Presentation - Baystreet.ca
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026 - marketscreener.com
A live briefing will cover a platform designed to help immune cells kill cancer - Stock Titan
EBITDA per share of GT Biopharma Inc – FWB:OXI - TradingView
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum BuildsSuperTrend - siam.in
GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum BuildsFactor Rotation - vinanet.vn
GT Biopharma Implements Reverse Stock Split, Streamlines Capital Structure - TipRanks
GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum BuildsInitial Balance - dars.gov.et
GTBP stock holds steady as GT Biopharma advances TriKE cancer pipeline - ad-hoc-news.de
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes - Eastern Progress
Stock Quotes, Business News and Data from Stock Markets | MSN Money - MSN
GTBP Q1 2026 Earnings: EPS Misses Estimates as Stock Drops 3.72%Dividend Cut Risk - vinanet.vn
GT Biopharma Shareholders Approve Reverse Split and Incentive Plan - TipRanks
GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes - Stock Titan
GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million - scanx.trade
Gt Biopharma Reports Second Quarter 2026 Financial Results - TradingView
1.35%
자본화:
|
볼륨(24시간):